My optimistic hope is that it still revolves aroun

My optimistic hope is that it still revolves around the continuation of the phase 1 trial and the peer reviewed paper which is, if I recall correctly, complete but still being peer reviewed. I think that Dana Farber has got CTIX somewhat backed into a corner on this one. DF can't stop CTIX from sharing, hence why CTIX has provided the information to the FDA, but they certainly can threaten to stop participating in the drug trial or in any other K work if CTIX releases data to the general public before DF is ready to put their name on it. It's been discussed before and I believe it still to be the case that DF is EXTREMELY excited about K performance and the potential ramifications in the cancer world. However; they are not about to make a 'cold-fusion' type announcement until they are confident that they can back it up with credible scientific data. Therefore; Leo and company are SOL until DF feels comfortable with their results and the third party peer reviewed paper is published.